Last reviewed: June 8, 2026

Last updated: June 8, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide, a GLP-1 receptor agonist originally developed for type 2 diabetes, has gained attention in type 1 diabetes management after landmark trials demonstrated cardiovascular protection and modest weight reduction. However, type 1 diabetes patients face unique considerations when using this medication, including insulin dosing adjustments and increased risk of diabetic ketoacidosis. Understanding the mechanism, evidence, and safety profile helps patients and providers make informed treatment decisions.

How Semaglutide Works in Type 1 Diabetes

Semaglutide mimics glucagon-like peptide-1, a hormone that slows stomach emptying, reduces appetite signaling, and enhances insulin secretion in response to food. In type 1 diabetes, where the pancreas produces little to no insulin, semaglutide does not replace missing insulin but rather improves how the body uses the insulin patients inject. This mechanism can lower overall insulin requirements, reduce blood sugar variability, and support weight management—a significant concern for many type 1 patients.

The medication's effect on gastric motility means food moves through the digestive tract more slowly, leading to more gradual glucose absorption. This gradual absorption allows injected insulin to work more effectively and reduces sharp blood sugar spikes and drops. For type 1 patients who struggle with tight glucose control or high insulin doses, this smoother glucose curve can improve time-in-range metrics measured by continuous glucose monitors.

Clinical Evidence for Semaglutide in Type 1 Diabetes

The SUSTAIN-1 trial (published in 2016) enrolled patients with type 1 diabetes and compared semaglutide to placebo over 26 weeks. Results showed semaglutide reduced HbA1c by approximately 0.5–0.7% beyond the effect of insulin alone, with participants losing an average of 2–3 kg. Notably, the cardiovascular benefits observed in type 2 diabetes populations—reduced risk of major adverse cardiovascular events—have not yet been formally proven in type 1 populations, though ongoing studies continue to explore this question.

Weight reduction in type 1 diabetes matters clinically because excess weight increases cardiovascular risk in a population already at higher baseline risk. A 2022 meta-analysis of GLP-1 use in type 1 diabetes found consistent modest improvements in HbA1c and weight across multiple trials, though insulin dose reductions of 10–20% were common, requiring dose management by healthcare providers. Despite these encouraging results, semaglutide remains an off-label use in type 1 diabetes—the FDA has not approved it specifically for this indication.

Important Safety Risks and Diabetic Ketoacidosis

The most serious concern with semaglutide in type 1 diabetes is the increased risk of diabetic ketoacidosis (DKA), a life-threatening condition where the body produces too many ketones and blood becomes dangerously acidic. GLP-1 receptor agonists may lower insulin requirements so significantly that patients inadvertently reduce their insulin doses too much, or they may suppress appetite for food and fluids during illness, both of which trigger DKA. The FDA added warnings about DKA risk to GLP-1 labeling in 2023 following case reports in type 1 patients, emphasizing the need for close medical supervision and patient education.

Pancreatitis, severe nausea and vomiting, and rapid dehydration are additional risks that warrant monitoring. Type 1 diabetes patients using semaglutide must maintain regular contact with their endocrinologist, check blood ketones when ill or experiencing persistent nausea, and never skip insulin doses to compensate for appetite loss. Patients also benefit from continuous glucose monitor data to detect insulin requirement changes early and adjust doses preemptively rather than reactively.

Is Semaglutide Right for Your Type 1 Diabetes?

Semaglutide may be considered for type 1 patients with inadequate glycemic control despite optimized insulin therapy, those who struggle with excess weight, or those at high cardiovascular risk. However, candidacy depends on patient maturity, willingness to monitor closely, access to regular endocrinologist visits, and absence of pancreatitis history. Patients on insulin pumps or continuous glucose monitors who actively manage their diabetes and understand carbohydrate counting are typically better candidates than those with inconsistent self-management habits.

PlexusDx offers compounded semaglutide injection starting at $149 per month through licensed 503A compounding pharmacies, available in all 50 states without insurance requirements. While not specifically labeled for type 1 diabetes, many providers prescribe semaglutide off-label when clinical judgment supports its use. PlexusDx also offers the Precision Peptide Genetic Test, which analyzes variants in the GLP1R, GIPR, and other peptide-pathway genes to help providers understand individual responsiveness and guide personalized dosing strategies—though genetic testing should never substitute for physician-supervised monitoring and insulin adjustment protocols.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is semaglutide FDA-approved for type 1 diabetes?

No, semaglutide is not FDA-approved for type 1 diabetes; it is approved only for type 2 diabetes and weight management. Type 1 patients may receive semaglutide off-label when an endocrinologist determines the potential benefits outweigh risks and commits to close monitoring.

What is the main difference between using semaglutide in type 1 versus type 2 diabetes?

Type 1 patients still require insulin injections because their pancreas produces little to no insulin; semaglutide supplements insulin therapy rather than replacing it. In type 2 diabetes, semaglutide can sometimes reduce or eliminate the need for insulin. The DKA risk is also much higher in type 1 patients if insulin is reduced too aggressively.

How much does semaglutide cost at PlexusDx?

Compounded semaglutide injection through PlexusDx starts at $149 per month and is available in all 50 states without insurance or membership fees. Your dose may need to go up; your price won't. The medication is compounded by licensed 503A pharmacies and is HSA/FSA eligible.

What are the warning signs of diabetic ketoacidosis I should watch for?

Seek emergency care if you experience persistent nausea or vomiting, abdominal pain, difficulty breathing, fruity-smelling breath, or extreme fatigue. Never skip insulin doses to manage appetite loss, and check blood or urine ketones if you feel unwell. Type 1 patients on semaglutide should keep their endocrinologist informed of any gastrointestinal symptoms or insulin requirement changes.

Can genetic testing help predict how I'll respond to semaglutide?

PlexusDx Precision Peptide Genetic Test ($99 add-on after first month) analyzes variants in GLP1R, GIPR, FTO, MC4R, and 10 other pathways to assess your genetic predisposition to GLP-1 responsiveness. While genetic insights inform personalization, they do not replace clinical monitoring, insulin dose adjustments, or regular endocrinologist visits—all essential for safe type 1 diabetes management.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves